Cargando…
Endocrine determinants of incident sarcopenia in middle-aged and elderly European men
BACKGROUND: In men, the long-term consequences of low serum levels of sex steroids, vitamin D metabolites, and insulin-like growth factor 1 (IGF-1) on the evolution of muscle mass, muscle strength, or physical performance are unclear. Moreover, there are no data about the relationship between these...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575556/ https://www.ncbi.nlm.nih.gov/pubmed/26401471 http://dx.doi.org/10.1002/jcsm.12030 |
_version_ | 1782390793412018176 |
---|---|
author | Gielen, Evelien O'Neill, Terence W Pye, Stephen R Adams, Judith E Wu, Frederick C Laurent, Michaël R Claessens, Frank Ward, Kate A Boonen, Steven Bouillon, Roger Vanderschueren, Dirk Verschueren, Sabine |
author_facet | Gielen, Evelien O'Neill, Terence W Pye, Stephen R Adams, Judith E Wu, Frederick C Laurent, Michaël R Claessens, Frank Ward, Kate A Boonen, Steven Bouillon, Roger Vanderschueren, Dirk Verschueren, Sabine |
author_sort | Gielen, Evelien |
collection | PubMed |
description | BACKGROUND: In men, the long-term consequences of low serum levels of sex steroids, vitamin D metabolites, and insulin-like growth factor 1 (IGF-1) on the evolution of muscle mass, muscle strength, or physical performance are unclear. Moreover, there are no data about the relationship between these hormones and incident sarcopenia defined as low muscle mass and function. The aim of this study was to determine whether the baseline levels of sex hormones, vitamin D metabolites, and IGF-1 predict changes in muscle mass, muscle strength, physical performance, and incident sarcopenia. METHODS: In 518 men aged 40–79 years, recruited for participation in the European Male Ageing Study, total, free, and bioavailable testosterone (T), oestradiol (E), sex hormone-binding globulin, IGF-1, 25-hydroxyvitamin D (25OHD), 1,25-dihydroxyvitamin D (1,25(OH)(2)D), and parathyroid hormone were assessed at baseline. Appendicular lean mass (aLM), gait speed, and grip strength were measured at baseline and after a mean follow-up of 4.3 years. Sarcopenia was defined by the definition of Baumgartner (relative aLM ≤7.26 kg/m(2)), the International Working Group on Sarcopenia (IWGS), and the European Working Group on Sarcopenia in Older People (EWGSOP). RESULTS: aLM significantly decreased from age 50 years, while gait speed and grip strength significantly decreased from age 70 years. The incidence of sarcopenia by the definitions of Baumgartner, IWGS, and EWGSOP was 8.1%, 3.0%, and 1.6%, respectively. After adjustment for age, centre, body mass index, smoking, and number of comorbidities at baseline, baseline levels of T and vitamin D metabolites were not associated with change in aLM, gait speed, and/or grip strength, while a high baseline level of total E(2) was associated with a greater decrease in aLM. In men aged ≥70 years, low IGF-1 was associated with a greater decrease in gait speed. Baseline endocrine variables were not independently associated with an increased risk of incident sarcopenia by any definition. CONCLUSIONS: Low levels of T and 25OHD do not predict loss of muscle mass, gait speed, or grip strength in middle-aged and elderly community-dwelling European men. Low IGF-1 predicts change in gait speed in men aged ≥70 years. |
format | Online Article Text |
id | pubmed-4575556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-45755562015-09-23 Endocrine determinants of incident sarcopenia in middle-aged and elderly European men Gielen, Evelien O'Neill, Terence W Pye, Stephen R Adams, Judith E Wu, Frederick C Laurent, Michaël R Claessens, Frank Ward, Kate A Boonen, Steven Bouillon, Roger Vanderschueren, Dirk Verschueren, Sabine J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: In men, the long-term consequences of low serum levels of sex steroids, vitamin D metabolites, and insulin-like growth factor 1 (IGF-1) on the evolution of muscle mass, muscle strength, or physical performance are unclear. Moreover, there are no data about the relationship between these hormones and incident sarcopenia defined as low muscle mass and function. The aim of this study was to determine whether the baseline levels of sex hormones, vitamin D metabolites, and IGF-1 predict changes in muscle mass, muscle strength, physical performance, and incident sarcopenia. METHODS: In 518 men aged 40–79 years, recruited for participation in the European Male Ageing Study, total, free, and bioavailable testosterone (T), oestradiol (E), sex hormone-binding globulin, IGF-1, 25-hydroxyvitamin D (25OHD), 1,25-dihydroxyvitamin D (1,25(OH)(2)D), and parathyroid hormone were assessed at baseline. Appendicular lean mass (aLM), gait speed, and grip strength were measured at baseline and after a mean follow-up of 4.3 years. Sarcopenia was defined by the definition of Baumgartner (relative aLM ≤7.26 kg/m(2)), the International Working Group on Sarcopenia (IWGS), and the European Working Group on Sarcopenia in Older People (EWGSOP). RESULTS: aLM significantly decreased from age 50 years, while gait speed and grip strength significantly decreased from age 70 years. The incidence of sarcopenia by the definitions of Baumgartner, IWGS, and EWGSOP was 8.1%, 3.0%, and 1.6%, respectively. After adjustment for age, centre, body mass index, smoking, and number of comorbidities at baseline, baseline levels of T and vitamin D metabolites were not associated with change in aLM, gait speed, and/or grip strength, while a high baseline level of total E(2) was associated with a greater decrease in aLM. In men aged ≥70 years, low IGF-1 was associated with a greater decrease in gait speed. Baseline endocrine variables were not independently associated with an increased risk of incident sarcopenia by any definition. CONCLUSIONS: Low levels of T and 25OHD do not predict loss of muscle mass, gait speed, or grip strength in middle-aged and elderly community-dwelling European men. Low IGF-1 predicts change in gait speed in men aged ≥70 years. John Wiley & Sons, Ltd 2015-09 2015-04-27 /pmc/articles/PMC4575556/ /pubmed/26401471 http://dx.doi.org/10.1002/jcsm.12030 Text en © 2015 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Gielen, Evelien O'Neill, Terence W Pye, Stephen R Adams, Judith E Wu, Frederick C Laurent, Michaël R Claessens, Frank Ward, Kate A Boonen, Steven Bouillon, Roger Vanderschueren, Dirk Verschueren, Sabine Endocrine determinants of incident sarcopenia in middle-aged and elderly European men |
title | Endocrine determinants of incident sarcopenia in middle-aged and elderly European men |
title_full | Endocrine determinants of incident sarcopenia in middle-aged and elderly European men |
title_fullStr | Endocrine determinants of incident sarcopenia in middle-aged and elderly European men |
title_full_unstemmed | Endocrine determinants of incident sarcopenia in middle-aged and elderly European men |
title_short | Endocrine determinants of incident sarcopenia in middle-aged and elderly European men |
title_sort | endocrine determinants of incident sarcopenia in middle-aged and elderly european men |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575556/ https://www.ncbi.nlm.nih.gov/pubmed/26401471 http://dx.doi.org/10.1002/jcsm.12030 |
work_keys_str_mv | AT gielenevelien endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT oneillterencew endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT pyestephenr endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT adamsjudithe endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT wufrederickc endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT laurentmichaelr endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT claessensfrank endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT wardkatea endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT boonensteven endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT bouillonroger endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT vanderschuerendirk endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen AT verschuerensabine endocrinedeterminantsofincidentsarcopeniainmiddleagedandelderlyeuropeanmen |